Loading
A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC is a phase 3 interventional study registered as NCT05884398 by Janssen Research & Development, LLC, with 420 participants enrolled, started 2023-08-31 and due to reach its primary completion in 2026-10-12. Interventions recorded: Apalutamide, Androgen-deprivation Therapy (ADT). Conditions listed: Metastatic Castrate-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors, Prostate cancer.